GlassScriptPhysician profile
Jessica A Thomas
NPI 1235715715
$1,592.96
in general payments reported to CMS, 2019-2025
24 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $481 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.97 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $212.66 | 2024-2025 | Blincyto, Kyprolis, Blincyto |
| Caris Mpi, INC. | $205.29 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $174.12 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $157.89 | 2025 | Imfinzi, Lynparza |
| Hologic Sales and Service, LLC | $81.39 | 2025 | Magseed |
| Alexion Pharmaceuticals, INC. | $74.99 | 2024 | Soliris |
| Regeneron Healthcare Solutions, INC. | $72.05 | 2024-2025 | Libtayo |
| Geron Corporation | $63.84 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $58.27 | 2024-2025 | Iclusig, Fruzaqla, Ninlaro |
| Genentech USA, INC. | $52.62 | 2024-2025 | Venclexta, Polivy |
| Genmab U.S., INC. | $50.68 | 2024-2025 | Epkinly |
| Janssen Biotech, INC. | $50.28 | 2024-2025 | Rybrevant, Talvey, Darzalex |
| Lilly USA, LLC | $41.04 | 2024-2025 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $40.81 | 2025 | |
| Sobi, INC | $39.64 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $35.65 | 2025 | Enjaymo |
| Adaptive Biotechnologies Corporation | $35.58 | 2025 | Clonoseq |
| Adc Therapeutics America, INC. | $27.11 | 2024 | |
| Astellas Pharma US INC | $25.53 | 2025 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $24.87 | 2025 | Opdualag |
| Array Biopharma INC | $19.57 | 2025 | Tukysa, Braftovi, Mektovi |
| Azurity Pharmaceuticals, INC. | $17.47 | 2025 | Danziten |
| Deciphera Pharmaceuticals INC. | $17.11 | 2025 | Qinlock |
| Teva Pharmaceuticals USA, INC. | $14.50 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.